公 告

Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, and Acelity today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire the regenerative medicine company LifeCell for $2.9 billion in cash, subject to customary adjustments.

艾尔建公司于12月20日宣布以29亿美元收购再生医学公司LifeCell。

- Entry into Regenerative Medicine Creates a World-Class Aesthetic and Regenerative Medicine Business in Plastic Surgery

• 本次收购为艾尔建在整形外科领域建立世界级医美及再生医学业务奠定了基础；

- Immediately Accretive Acquisition Expected to Generate ~$450 Million in Revenues, ~75% Gross Margin and ~40% Operating Margin in 2016

• 预计LifeCell将在2016年内为艾尔建带来4亿5千万美元的收入，毛利润75%，营运利润率40%；

- Key Products Include ALLODERM® and STRATTICE™ Tissue Matrices Commonly Used in Breast Reconstruction and Abdominal Wall Surgeries

• LifeCell公司目前的主要产品包括用于乳房重建和腹壁整形术中的组织基质产品ALLODERM® 和 STRATTICE™返回搜狐，查看更多

责任编辑：